Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21266720 | 0.91 | CYP1A1 (0.37) | BRD4CYP1B1CYP1A1CYP1A2CYP2E1 | |
| SCHEMBL21266723 | 0.79 | ALDH1A1 (0.41) | CYP1A2CYP3A4FGFR1FGFR2FGFR4 | |
| SCHEMBL21266722 | 0.78 | CYP1A2 (0.40) | BRD4CYP1A2CYP3A4BRD9ALDH1A1 | |
| SCHEMBL21266744 | 0.73 | BRD4 (0.34) | BRD4CYP1B1CYP1A1CYP1A2CYP2E1 | |
| SCHEMBL21266733 | 0.71 | FGFR2 (0.49) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL15413109 | 0.69 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9FGFR4ALDH1A1 | |
| SCHEMBL859740 | 0.67 | BRD4 (0.39) | BRD4ALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL13074741 | 0.65 | BRD4 (0.41) | BRD4CYP1A2ALDH1A1GAAHPGD | |
| SCHEMBL13058495 | 0.65 | BRD4 (0.35) | BRD4ALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL15618343 | 0.65 | CASP3 (0.48) | CYP1B1CYP1A1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011869-B1 | CRYSTAL FORM D OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREFOR | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2023-11-15 | — | — | EP | disclosed |
| EP-4011867-B1 | CRYSTAL FORMS C AND E OF PYRAZIN-2(1H)-ONE COMPOUND AND PREPARATION METHOD THEREFOR | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4011866-B1 | CRYSTALLINE FORM A AND CRYSTALLINE FORM B OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREOF | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11680061-B2 | Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-11680061-B2 | Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-11535609-B2 | Pyrazine-2(1H)-ketone compound preparation method | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-3750880-B1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2022-12-21 | — | — | EP | disclosed |
| EP-4011869-A1 | CRYSTAL FORM D OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREFOR | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011867-A1 | CRYSTAL FORMS C AND E OF PYRAZIN-2(1H)-ONE COMPOUND AND PREPARATION METHOD THEREFOR | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011868-A1 | PYRAZINE-2(1H)-KETONE COMPOUND PREPARATION METHOD | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011866-A1 | A CRYSTALLINE FORM AND B CRYSTALLINE FORM OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-29 | — | — | US | disclosed |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021023194-A1 | CRYSTAL FORMS C AND E OF PYRAZIN-2(1H)-ONE COMPOUND AND PREPARATION METHOD THEREFOR | 漳州片仔癀药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023192-A1 | A CRYSTALLINE FORM AND B CRYSTALLINE FORM OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREOF | 漳州片仔癀药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023193-A1 | PYRAZINE-2(1H)-KETONE COMPOUND PREPARATION METHOD | 漳州片仔癀药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023195-A1 | CRYSTAL FORM D OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREFOR | 漳州片仔癀药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| EP-3750880-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154364-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535609-B2 | Pyrazine-2(1H)-ketone compound preparation method | PDK2, HSD17B7, CYP2F1 | BRD4 1087/4885CYP1B1 36/4885CYP1A1 93/4885 |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | FGFR1, FGFR2, FGFR3 | BRD4 658/4885CYP1B1 448/4885CYP1A1 1388/4885 |
| US-11680061-B2 | Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor | WEE2, WEE1, CYP4F11 | BRD4 3690/4885CYP1B1 27/4885CYP1A1 150/4885 |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | FGFR1, FGFR2, FGFR3 | BRD4 658/4885CYP1B1 448/4885CYP1A1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.